MorphoSys AG (ETR:MOR) Receives Average Rating of “Hold” from Brokerages

Share on StockTwits

Shares of MorphoSys AG (ETR:MOR) have earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is €100.78 ($117.18).

A number of brokerages recently issued reports on MOR. JPMorgan Chase & Co. set a €50.00 ($58.14) target price on shares of Brenntag and gave the stock a “buy” rating in a research report on Tuesday. Goldman Sachs Group lowered shares of Metcash from a “conviction-buy” rating to a “neutral” rating in a research report on Monday, June 24th. Royal Bank of Canada raised their target price on shares of from GBX 2,400 ($31.36) to GBX 2,800 ($36.59) and gave the stock an “outperform” rating in a research report on Monday, June 24th. Independent Research set a €96.00 ($111.63) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research report on Thursday, July 4th. Finally, Berenberg Bank restated a “hold” rating and set a GBX 1,581 ($20.66) target price on shares of in a research report on Tuesday, June 11th.

Shares of MOR traded up €2.80 ($3.26) during mid-day trading on Friday, reaching €97.75 ($113.66). 187,305 shares of the company’s stock were exchanged, compared to its average volume of 153,687. MorphoSys has a 52-week low of €76.45 ($88.90) and a 52-week high of €124.90 ($145.23). The stock’s 50-day simple moving average is €87.32. The company has a market cap of $3.08 billion and a P/E ratio of -52.61. The company has a debt-to-equity ratio of 8.65, a quick ratio of 7.53 and a current ratio of 7.75.

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Featured Article: What is a front-end load?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Macquarie Downgrades Viacom  to Neutral
Macquarie Downgrades Viacom to Neutral
Contrasting Toshiba  & The Competition
Contrasting Toshiba & The Competition
Head to Head Survey: Fanhua  & Its Competitors
Head to Head Survey: Fanhua & Its Competitors
Head-To-Head Survey: Landstar  & Braskem
Head-To-Head Survey: Landstar & Braskem
Deutsche Bank Lowers Deere & Company  Price Target to $155.00
Deutsche Bank Lowers Deere & Company Price Target to $155.00
OMV  Downgraded by Goldman Sachs Group to Neutral
OMV Downgraded by Goldman Sachs Group to Neutral


 
© 2006-2019 Zolmax.